全球心房颤动市场 – 行业趋势及 2029 年预测

心房颤动市场分析及规模

最常见的心律失常是心房颤动，当心脏上腔（心房）接收不规则电脉冲时就会发生这种情况。因此，心跳变得不规律且快速。心房颤动可能导致心率每分钟 100 至 175 次。心房颤动会导致思维混乱、头晕、疲倦和昏厥。增加 AF 发病率的其他因素包括全球肥胖和心脏病患病率增加，以及 COVID-19 近期的发展和对 AF 的影响。

Data Bridge Market Research 分析了 2022-2029 年预测期内全球心房颤动市场的增长率。在上述预测期内，全球心房颤动市场的预期复合年增长率趋于 12.0% 左右。2021 年市场价值为 20.4495 亿美元，到 2029 年将增长至 50.6322 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

心房颤动市场范围和细分

Market Definition

Atrial Fibrillation (AF) is the most common type of arrhythmia that leads to an irregular and fast heart rhythm. Since last two decades, prevalence of atrial fibrillation cases is seen higher across the globe. According to American Heart Association, almost 33.5 million people were suffering from atrial fibrillation around the world in 2013. Furthermore, approximately 200,000 to 400,000 new atrial fibrillation cases are diagnosed every year in the U.S. This rise in the number of AF cases are prompting the growth of the market.

Global Atrial Fibrillation Market Dynamics

Drivers

• Increase in Elderly Population

The expansion of the atrial fibrillation market is prompted by rise in the frequency of atrial fibrillation in the elderly population, technical developments, and a preference for catheter ablation for cardiac arrhythmia therapy. Thus, it is helpful in driving the market growth.

• Increase in Developed Treatments

Catheter ablation is a technique used to treat irregular cardiac rhythms when medicines are ineffective. It is a low-risk, minimally invasive method for the treatment of cardiac arrhythmias. The catheter ablation technology removes abnormal cardiac tissues that cause irregular heartbeats. In the treatment of cardiac arrhythmias, catheter ablation has a 95.0 percent success rate.

Opportunities

• Rise in Cardiac Monitors

The surgical segment generated the most revenue in 2020 due to an increase in the adoption of cardiac monitoring systems during the treatment of atrial fibrillation. The rise in the number of patients suffering from arrhythmia or an irregular heartbeat has resulted in an increase in the demand for cardiac monitors.

• Advanced Technology

Development in technology is pushing the market growth of atrial fibrillation. Advanced catheter ablation for the treatment of atrial fibrillation and lowering the risk of stroke in patients is manufactured by important players. For instance, Abbott Laboratories, a maker of healthcare products and medical devices, developed the TactiFlex PAF IDE ablation catheter in August 2020, which is used to treat patients with paroxysmal atrial fibrillation, an irregular heartbeat. It features sensors for patients who have symptoms of atrial fibrillation (AFib) that can't be addressed with medication.

Restraints/Challenges

• High Costs

This technology is definitely helping in outgrowing the market size but one factor that is limiting the growth is the excessive high price of the treatment process. It is costly and thus it is not applicable everytime to use it tremendously.  

This atrial fibrillation market provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the atrial fibrillation market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Atrial Fibrillation Market

Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business, and its long-term repercussions are expected to have an influence on industry growth during the forecast period.

COVID-19 epidemic delayed production of numerous atrial fibrillation products. Furthermore, with the launch of the COVID-19 vaccine on the market, the number of COVID-19 cases is predicted to decrease in the future. As a result, companies that specialise in atrial fibrillation have reopened at full capacity. By the beginning of 2022, it is predicted to expand and recover the atrial fibrillation market share. Following the drop in COVID-19 infection cases, equipment and machinery manufacturers must focus on protecting their employees, operations, and supply networks in order to respond to urgent emergencies and build new working procedures.

Global Atrial Fibrillation Market Scope

The global atrial fibrillation market is segmented on the basis of product, type and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Surgical Devices
• Non-Surgical Devices
• Pharmacological Drugs

Type

• Paroxysmal
• Others

End User

• Hospitals
• Electrophysiology Labs
• Ambulatory Surgical Centers

Atrial Fibrillation Market Regional Analysis/Insights

The global atrial fibrillation market is analyzed and market size insights and trends are provided by type, product, and end user as referenced above.

心房颤动市场的主要国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于医疗保健支出的快速增长以及基础设施的普遍改善，北美在心房颤动市场占据主导地位。

由于老年人口不断增加和人民可支配收入不断提高，预计亚太地区将在 2022 年至 2029 年的预测期内以最高增长率增长。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和全球心房颤动市场份额分析

心房颤动市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对心房颤动市场的关注有关。

全球心房颤动市场的主要参与者包括：

• 雅培（美国）
• 强生私人有限公司（美国）
• 微创医疗科学有限公司。（中国）
• 波士顿科学公司（美国）。
• 美敦力（美国）
• BIOTRONIK SE & Co. KG（美国）
• Koninklijke Philips NV（荷兰）
• 西门子（美国）
• AtriCure, Inc（美国）
• 赛诺菲 (美国)
• Biosense Webster, Inc（美国）
• CardioFocus。（美国）
• 百时美施贵宝公司（美国）
• 勃林格殷格翰国际有限公司 (美国)
• 通用电气公司（美国）
• 辉瑞公司（美国）

SKU-55688